TELA Bio (TELA)
(Delayed Data from NSDQ)
$2.65 USD
+0.05 (1.92%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $2.67 +0.02 (0.75%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for TELA Bio, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 47 | 42 | 44 | 74 | 55 |
Receivables | 10 | 7 | 4 | 3 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 13 | 12 | 8 | 4 | 5 |
Other Current Assets | 2 | 2 | 3 | 2 | 2 |
Total Current Assets | 72 | 62 | 59 | 83 | 64 |
Net Property & Equipment | 2 | 2 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 3 | 2 | 3 | 3 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 78 | 68 | 63 | 86 | 68 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 2 | 1 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 15 | 11 | 8 | 6 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 17 | 12 | 11 | 7 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 41 | 40 | 31 | 31 | 30 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 1 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 59 | 54 | 42 | 37 | 37 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 340 | 288 | 250 | 246 | 199 |
Retained Earnings | -321 | -274 | -230 | -197 | -168 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 19 | 14 | 20 | 49 | 31 |
Total Liabilities & Shareholder's Equity | 78 | 68 | 63 | 86 | 68 |
Total Common Equity | 19 | 14 | 20 | 49 | 31 |
Shares Outstanding | 24.40 | 19.10 | 14.50 | 14.40 | 11.40 |
Book Value Per Share | 0.77 | 0.75 | 1.39 | 3.40 | 2.72 |
Fiscal Year End for TELA Bio, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 27 | 37 | 47 | 58 | 65 |
Receivables | 9 | 10 | 10 | 8 | 8 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 13 | 14 | 13 | 14 | 14 |
Other Current Assets | 2 | 2 | 2 | 2 | 2 |
Total Current Assets | 51 | 63 | 72 | 82 | 89 |
Net Property & Equipment | 2 | 2 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 2 | 2 | 2 | 2 |
Deposits & Other Assets | 3 | 3 | 0 | 0 | 0 |
Total Assets | 60 | 72 | 78 | 87 | 94 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 3 | 2 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 12 | 15 | 12 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 15 | 15 | 17 | 15 | 13 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 41 | 41 | 41 | 40 | 40 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 2 | 1 | 1 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 57 | 57 | 59 | 57 | 54 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 342 | 341 | 340 | 338 | 337 |
Retained Earnings | -339 | -327 | -321 | -308 | -297 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 3 | 14 | 19 | 31 | 40 |
Total Liabilities & Shareholder's Equity | 60 | 72 | 78 | 87 | 94 |
Total Common Equity | 3 | 14 | 19 | 31 | 40 |
Shares Outstanding | 24.60 | 24.60 | 24.40 | 24.40 | 24.40 |
Book Value Per Share | 0.12 | 0.58 | 0.77 | 1.25 | 1.64 |